- News & Events
- Contact Us
|View printer-friendly version|
|Amgen Announces Results Of Phase 3 Study Of Enbrel Dosed Once Weekly|
|FOR IMMEDIATE RELEASE
THOUSAND OAKS, Calif., December 5, 2002 – Amgen (NASDAQ: AMGN) today announced that a clinical study assessing 50 mg of ENBRELâ (etanercept) administered once weekly demonstrated similar efficacy, tolerability and pharmacokinetics to that of 25 mg of ENBREL administered twice weekly. “We are pleased with these results and look forward to presenting comprehensive results from this study at a future scientific meeting,” said Dr. Daniel Burge, Amgen's vice president of clinical research. “This study suggests that physicians may have the opportunity to combine the benefits and proven long-term tolerability profile of ENBREL with the flexibility of either once weekly or twice weekly dosing,” said Kevin Young, vice president and general manager of Amgen's Inflammation Business Unit.
Rheumatologists have become familiar with the benefits and proven long-term tolerability profile of ENBREL, having treated over 129,000 patients in over four years of post-marketing experience. ENBREL acts by binding TNF, one of the dominant inflammatory cytokines or regulatory proteins that play an important role in both normal immune function and the cascade of reactions that causes the inflammatory process of psoriatic arthritis and RA. The binding of ENBREL to TNF renders the bound TNF biologically inactive, resulting in significant reduction in inflammatory activity.
Important Treatment Considerations
ABOUT ENBREL OR INFECTIONS.
Please see full Product Information.
Amgen is a global biotechnology company that discovers, develops, manufactures and markets important human therapeutics based on advances in cellular and molecular biology.
This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent Form 10-Q. Amgen conducts research in the biotechnology/pharmaceutical field where movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. In addition, sales of our products are affected by reimbursement policies imposed by third party payors, including governments, private insurance plans and managed care providers. These government regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. Because forward-looking statements involve risks and uncertainties, actual results may differ materially from current results expected by Amgen. Amgen is providing this information as of December 5, 2002, and expressly disclaims any duty to update information contained in this press release.
EDITOR'S NOTE: An electronic version of this news release may be accessed via www.amgen.com. Visit the Corporate Center and click on Amgen News. Journalists and media representatives may sign up to receive all news releases electronically at time of announcement by filling out a short form.